Skip to content
You are now leaving to visit

New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington’s Disease

First drug to demonstrate lowering of mutant huntingtin, the disease-causing protein, in people with Huntington’s disease CARLSBAD, Calif. , April 24, 2018 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today presented top-line data from the Phase